$511 Million is the total value of Opaleye Management Inc.'s 55 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 68.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OCUL | OCULAR THERAPEUTIX INC | $45,540,000 | -8.6% | 5,984,200 | 0.0% | 8.91% | -11.5% | |
| TARA | Buy | PROTARA THERAPEUTICS INC | $43,059,000 | -33.5% | 2,558,472 | +15.8% | 8.42% | -35.6% |
| ETON | ETON PHARMACEUTICALS INC | $28,756,000 | +45.0% | 3,640,000 | 0.0% | 5.62% | +40.4% | |
| CRDF | Buy | CARDIFF ONCOLOGY INC | $24,571,000 | +731.2% | 1,731,600 | +193.5% | 4.80% | +704.9% |
| AFIB | New | ACUTUS MEDICAL INC | $22,350,000 | – | 749,990 | +100.0% | 4.37% | – |
| CCXI | Sell | CHEMOCENTRYX INC | $19,509,000 | -6.3% | 356,000 | -1.5% | 3.82% | -9.3% |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $16,636,000 | -28.4% | 1,386,300 | -1.0% | 3.25% | -30.7% |
| HROW | Buy | HARROW HEALTH INC | $16,541,000 | +17.2% | 2,959,000 | +9.2% | 3.24% | +13.5% |
| CDXS | CODEXIS INC | $16,436,000 | +2.2% | 1,400,000 | 0.0% | 3.21% | -1.1% | |
| EIDX | EIDOS THERAPEUTICS INC | $15,945,000 | +9.0% | 315,550 | 0.0% | 3.12% | +5.5% | |
| PCVX | New | VAXCYTE | $15,456,000 | – | 313,000 | +100.0% | 3.02% | – |
| CLDX | Sell | CELLDEX THERAPEUTICS INC | $14,711,000 | +5.7% | 992,000 | -7.4% | 2.88% | +2.3% |
| MGNX | Buy | MACROGENICS INC | $13,275,000 | -5.1% | 527,000 | +5.2% | 2.60% | -8.1% |
| DCPH | DECIPHERA PHARMACEUTICALS IN | $11,389,000 | -12.9% | 222,000 | 0.0% | 2.23% | -15.7% | |
| STXS | Sell | STEREOTAXIS INC | $10,817,000 | -30.9% | 3,021,436 | -14.0% | 2.12% | -33.1% |
| Sell | APTOSE BIOSCIENCES INC | $10,794,000 | -45.3% | 1,799,000 | -42.5% | 2.11% | -47.1% | |
| ATXI | Sell | AVENUE THERAPEUTICS INC | $10,664,000 | -4.3% | 984,692 | -4.9% | 2.09% | -7.3% |
| TGTX | Sell | TG THERAPEUTICS INC | $10,436,000 | +17.3% | 390,000 | -14.6% | 2.04% | +13.6% |
| TCON | New | TRACON PHARMACEUTICALS INC | $10,409,000 | – | 2,013,438 | +100.0% | 2.04% | – |
| FBIO | FORTRESS BIOTECH INC | $10,264,000 | 0.0% | 3,830,000 | 0.0% | 2.01% | -3.2% | |
| MYOV | MYOVANT SCIENCES LTD | $9,589,000 | -31.9% | 682,500 | 0.0% | 1.88% | -34.0% | |
| CMRX | Buy | CHIMERIX INC | $9,565,000 | +46.6% | 3,841,500 | +82.5% | 1.87% | +42.0% |
| MCRB | New | SERES THERAPEUTICS | $9,493,000 | – | 335,312 | +100.0% | 1.86% | – |
| AXGT | New | AXOVANT SCIENCES LTD | $9,421,000 | – | 2,039,100 | +100.0% | 1.84% | – |
| KNSA | Sell | KINIKSA PHARMACEUTICALS LTD | $8,778,000 | 0.0% | 338,000 | -1.9% | 1.72% | -3.2% |
| XOMA | Buy | XOMA CORP DEL | $8,572,000 | +4.4% | 455,000 | +9.5% | 1.68% | +1.1% |
| CERC | CERECOR INC | $7,678,000 | -12.4% | 3,372,500 | 0.0% | 1.50% | -15.2% | |
| BHVN | BIOHAVEN PHARMACEUTICAL HLDG | $7,434,000 | -11.1% | 114,350 | 0.0% | 1.45% | -13.9% | |
| ADMS | Buy | ADAMAS PHARMACEUTICALS INC | $6,130,000 | +149.4% | 1,487,800 | +55.0% | 1.20% | +141.7% |
| FGEN | Buy | FIBROGEN INC | $6,045,000 | +6.3% | 147,000 | +0.7% | 1.18% | +2.9% |
| TELA | Buy | TELA BIO INC | $5,989,000 | +84.8% | 362,074 | +44.8% | 1.17% | +79.1% |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $5,863,000 | +5.0% | 470,203 | +1.9% | 1.15% | +1.7% |
| MEIP | MEI PHARMA INC | $4,855,000 | -24.4% | 1,556,000 | 0.0% | 0.95% | -26.8% | |
| EDAP | Sell | EDAP TMS SAsponsored adr | $4,784,000 | +2.9% | 1,040,000 | -44.6% | 0.94% | -0.3% |
| CYTK | Sell | CYTOKINETICS INC | $4,521,000 | -36.7% | 208,800 | -31.1% | 0.88% | -38.7% |
| CRNX | Sell | CRINETICS PHARMACEUTICALS INC | $3,761,000 | -50.7% | 240,000 | -44.9% | 0.74% | -52.2% |
| FULC | New | FULCRUM THERAPEUTICS INC | $3,584,000 | – | 452,000 | +100.0% | 0.70% | – |
| LUMO | New | LUMOS PHARMA INC | $3,329,000 | – | 240,892 | +100.0% | 0.65% | – |
| KZR | New | KEZAR LIFE SCIENCES INC | $3,282,000 | – | 678,000 | +100.0% | 0.64% | – |
| VSTM | New | VERASTEM INC | $3,201,000 | – | 2,200,000 | +100.0% | 0.63% | – |
| CDTX | CIDARA THERAPEUTICS INC | $2,766,000 | -22.8% | 970,664 | 0.0% | 0.54% | -25.2% | |
| AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $2,659,000 | – | 375,000 | +100.0% | 0.52% | – |
| NERV | New | MINERVA NEUROSCIENCES INC | $2,440,000 | – | 767,400 | +100.0% | 0.48% | – |
| OM | New | OUTSET MED INC | $2,250,000 | – | 45,000 | +100.0% | 0.44% | – |
| EPIX | Buy | ESSA PHARMA INC | $1,872,000 | +72.5% | 271,350 | +55.1% | 0.37% | +67.1% |
| STRO | New | SUTRO BIOPHARMA INC | $1,467,000 | – | 146,000 | +100.0% | 0.29% | – |
| CFRX | New | CONTRAFECT INC | $1,194,000 | – | 226,127 | +100.0% | 0.23% | – |
| CNCE | New | CONCERT PHARMACEUTICALS INC | $982,000 | – | 100,000 | +100.0% | 0.19% | – |
| AMRN | Sell | AMARIN CORP PLCsponsored adr new | $947,000 | -69.9% | 225,000 | -50.5% | 0.18% | -70.9% |
| XFOR | New | X4 PHARMACEUTICALS INC | $508,000 | – | 75,000 | +100.0% | 0.10% | – |
| ONCT | New | ONCTERNAL THERAPEUTICS INC | $331,000 | – | 194,541 | +100.0% | 0.06% | – |
| PIRS | New | PIERIS PHARMACEUTICALS INC | $300,000 | – | 145,000 | +100.0% | 0.06% | – |
| INFI | New | INFINITY PHARMACEUTICALS INC | $137,000 | – | 3,171,800 | +100.0% | 0.03% | – |
| BLRX | BIOLINERX LTDsponsored ads | $33,000 | +13.8% | 16,667 | 0.0% | 0.01% | 0.0% | |
| MRUS | New | MERUS NV | $2,000 | – | 200 | +100.0% | 0.00% | – |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -51,225 | -100.0% | -0.08% | – |
| ASRT | Exit | ASSERTIO HOLDINGS INC | $0 | – | -880,000 | -100.0% | -0.15% | – |
| AUTL | Exit | AUTOLUS THERAPEUTICS PLCsponsored ads | $0 | – | -60,000 | -100.0% | -0.19% | – |
| FENC | Exit | FENNEC PHARMACEUTICALS INC | $0 | – | -171,000 | -100.0% | -0.29% | – |
| ARDX | Exit | ARDELYX INC | $0 | – | -471,600 | -100.0% | -0.66% | – |
| LQDA | Exit | LIQUIDIA TECHOLOGIES INC | $0 | – | -400,000 | -100.0% | -0.68% | – |
| KALA | Exit | KALA PHARMACEUTICALS INC | $0 | – | -361,000 | -100.0% | -0.77% | – |
| BTAI | Exit | BIOXCEL THERAPEUTICS INC | $0 | – | -94,000 | -100.0% | -1.01% | – |
| CPRX | Exit | CATALYST PHARMACEUTICALS INC | $0 | – | -1,155,000 | -100.0% | -1.08% | – |
| TCDA | Exit | TRICIDA INC | $0 | – | -238,300 | -100.0% | -1.32% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -495,000 | -100.0% | -1.38% | – |
| QURE | Exit | VAXCYTE | $0 | – | -270,400 | -100.0% | -1.73% | – |
| ODT | Exit | ODONATE THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -2.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.